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Abstract
Background: Impaired left atrial (LA) function is an early marker of cardiac dysfunction and predictor of adverse
cardiac events. Herein, we assess LA structure and function in hypertrophy in hypertrophic cardiomyopathy (HCM)
sarcomere mutation carriers with and without left ventricular hypertrophy (LVH).
Method: Seventy-three participants of the HCMNet study who underwent cardiovascular magnetic resonance
(CMR) imaging were studied, including mutation carriers with overt HCM (n = 34), preclinical mutation carriers
without HCM (n = 24) and healthy, familial controls (n = 15).
Results: LA volumes were similar between preclinical, control and overt HCM cohorts after covariate adjustment.
However, there was evidence of impaired LA function with decreased LA total emptying function in both
preclinical (64 ± 8%) and overt HCM (59 ± 10%), compared with controls (70 ± 7%; p = 0.002 and p = 0.005,
respectively). LA passive emptying function was also decreased in overt HCM (35 ± 11%) compared with controls
(47 ± 10%; p = 0.006). Both LAtotal emptying function and LA passive emptying function were inversely correlated
with the extent of late gadolinium enhancement (LGE; p = 0.005 and p < 0.05, respectively), LV mass (p = 0.02 and
p < 0.001) and interventricular septal thickness (p < 0.001 for both) and serum NT-proBNP levels (p < 0.001 for both).
Conclusion: LA dysfunction is detectable by CMR in preclinical HCM mutation carriers despite non-distinguishable
LV wall thickness and LA volume. LA function appears most impaired in subjects with overt HCM and a greater
extent of LV fibrosis.
Keywords: Cardiovascular magnetic resonance (CMR), Hypertrophic cardiomyopathy, Left Atrial function
Background
Hypertrophic cardiomyopathy (HCM) is caused by muta-
tions in genes encoding sarcomere proteins [1]. Impaired
left ventricular (LV) relaxation, altered myocardial energet-
ics, and increased myocardial extracellular volume (ECV)
have been demonstrated in HCM subjects without clinical
disease, indicating that sarcomere mutations cause cardiac
abnormalities prior to the establishment of LV hypertrophy
(LVH) [2–5]. While the clinical diagnosis of overt HCM is
defined by exceeding a threshold of LV wall thickness,
typically greater than 1.3 to 1.5 cm, genetic testing allows
for the early identification of at-risk family members when
LV wall thickness is still within the normal range (LVH−)
[6]. This unique scenario allows for the study of early-stage
disease in sarcomere mutation or genotype-positive/LVH-
negative (G+/LVH−) individuals, herein referred to as “pre-
clinical HCM”.
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Historically, LV morphology and function have been
extensively studied in HCM; however, evaluation of the
left atrium (LA) has been largely underutilized [7, 8]. An
increase in LA volume (LAV) has been established as a
marker of adverse cardiac events among broad groups of
patients with cardiovascular disease [9–13]. Recently,
data have shown that metrics of LA function can pro-
vide prognostic information beyond measurement of LA
volume. For example, early detection of LA dysfunction
may provide additional insight into the pathophysiology
and aid in the clinical management of common cardio-
vascular diseases such as atrial fibrillation, myocardial is-
chemia, heart failure and cardiomyopathy [9, 10, 12].
LA function can be comprehensively assessed by meas-
uring the three components that contribute to LV filling:
reservoir, conduit, and pump phases. The reservoir phase
starts at ventricular systole and encompasses LV isovolu-
metric contraction, ejection, and isovolumetric relaxation.
During the reservoir phase, blood is received from the
pulmonary veins and the LA fills, growing in volume as
the mitral valve remains closed. Next, the LA acts as a
conduit as the mitral valve opens and passive emptying
occurs. LAV decreases during early ventricular diastole,
driven by a suction effect on the LA as the LV relaxes and
expands. Lastly, the atrial pump phase occurs during late
ventricular diastole as the atrial muscle contracts and exe-
cutes an active pump function, concluding ventricular fill-
ing. Technically, the LA reservoir, conduit, and active
pump functions can be calculated from LAV at its max-
imum (end-systole, just prior to mitral valve opening),
minimum (end-diastole, at mitral valve closure), and im-
mediately before atrial contraction (before the electrocar-
diographic P-wave). From these three LAVs, total, passive,
and active emptying functions can be calculated
(LATEmF, LAPEmF and LAAEmF).
In this study, we hypothesized that LA function is ab-
normal in preclinical HCM mutation carriers, declines
further in those with overt HCM, and correlates with
other metrics of disease severity. To test these hypotheses,
we examined the relationship between LA function, clinical
parameters and established biomarkers for heart failure in a
well-characterized genotyped cohort with preclinical and
overt HCM and mutation-negative healthy family members.
Methods
Study population
HCMNet is a collaborative network comprised of 11 HCM
specialty centers in the United States (Additional file 1:
Table S1) [14]. This cross-sectional observational study was
performed from 2009 to 2011 of sarcomere mutation
carriers with clinically overt HCM (G+/LVH+), mutation
carriers without LVH (G+/LVH-), and healthy relatives who
do not carry the family’s mutation (G−/LVH- controls). LVH
was based on echocardiographic core laboratory
measurements and defined as a maximal LV wall thickness ≥
12 mm in adults or a z-score ≥ 3 in participants <18 years of
age. Genotype was confirmed in CLIA-approved
laboratories either prior to or in conjunction with
study enrollment. Variant interpretation was based on
standard criteria accounting for segregation, conserva-
tion, and absence from appropriate control popula-
tions [15]. Sarcomere mutations were required to be
classified as pathogenic or likely pathogenic by the
testing laboratory at enrollment. Pathogenicity was
reassessed at the time of data analysis and only those
that fulfilled current criteria as pathogenic or likely
pathogenic were included.
The 11 HCMNet centers were responsible for recruit-
ing and enrolling participants and carrying out study
procedures with standardized protocols. Institutional re-
view boards at each participating site approved the study
protocol and all participants provided written informed
consent or parental consent/youth assent. As part of the
HCMNet protocol, subjects underwent transthoracic echo-
cardiography, exercise testing and assessment of serum bio-
markers. CMR was performed for study participants when
there were no contraindications (e.g., implantable cardiac
device). Of 111 CMR studies performed in HCMNet,
approximately 20% (N = 24) could not be scored due to the
lack of diagnostic views in both 2- and 4-chamber views
necessary to accurately assess LA volumes. Fourteen
children under 15 years of age were not included due to
currently undefined reference values and z-scores for LA
function in children and the lack of normal controls to pro-
vide such values in this study cohort (n = 4). Therefore, a
total of 73 studies were scored for LA volumes and function
in this study.
CMR protocol
All images were acquired with electrocardiographic gat-
ing, breath-holding, and with the patient in a supine
position as previously described [3]. Each participant
was imaged on a 1.5 T or 3 T CMR system depending
on site technical availability. The standard CMR protocol
consisted of balanced cine steady-state free precession im-
aging for cardiac function and mass (repetition time, 2.4 ms;
echo time, 1.2 ms; spatial resolution, 1.4 × 1.8 × 8 mm,
temporal resolution ≤40 msec) [16]. For late gadolinium en-
hancement (LGE) imaging, a segmented inversion-recovery
pulse sequence was used starting 10–15 min after a single
bolus dose of 0.15-mmol/kg of gadolinium DTPA (Magne-
vist®, Bayer HealthCare, Whippany, New Jersey, USA). Cine
imaging and LV LGE imaging were obtained in 8 to 14
matching short-axis (8 mm thick with 0 mm spacing) as well
as 2, 3 and 4 chamber long-axis planes [9]. LV mass was de-
termined by tracing successive short axis images (excluding
papillary muscles from the volume) and multiplying the
myocardial muscle volume by 1.05 g/cm, indexed to body
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surface area (BSA) [17] (CIM software package version 6.2;
Auckland MR Imaging Research Group, University of
Auckland, Auckland, New Zealand) [18]. The thickness of
the LV wall was measured throughout the myocardium with
the largest measurement in each of four segments (anterior
and posterior septal, lateral and inferior) defined as the max-
imal wall thickness.
The extent of LGE was quantified by a semi-automatic de-
tection method using a previously validated research tool
(QMassMR, version 7.4; Medis, Leiden, the Netherlands).
The mass of LV LGE was measured in grams and was
expressed as a percentage of the total LV myocardial mass.
The core laboratory (Radiology and Imaging Sciences
Department, National Institutes of Health Clinical Center)
performed all CMR analyses by staff blinded to patient
genotype.
Left atrium analysis
A commercial software package (CVI 42, Circle Cardiovas-
cular Imaging, Calgary, Canada) was used to analyze LA
emptying function. LAV were measured at (1) the beginning
of LV diastole (defined as the frame immediately prior to
opening of the mitral leaflets, LAVmax), (2) the end of passive
LV filling (defined as the frame immediately prior to LA
contraction, LAVbac), and (3) the end of LA contraction
(LAVmin). The inferior LA border was defined as the plane
of the mitral annulus based on prior convention [9, 19]. To
calculate LAV, we measured LA length (from the midpoint
of the mitral annulus plane) and border (excluding the LA
appendage and pulmonary veins) in the two- and four-
chamber views. We then applied the biplane area-length
method: LAV= [(8/3π) x (4-chamber area) x (2-chamber
area)]/atrial length [19, 20]. As previously described [9, 10],
LAPEmF was calculated as (LAVmax - LAVbac)/LAVmax ×
100; LAAEmF as (LAVbac – LAVmin)/LAVbac × 100; and
LATEmF as (LAVmax - LAVmin)/ LAVmax × 100. Measure-
ments were made by investigators (HF and DV) blinded to
patient genotype and clinical history.
Transthoracic Echocardiography
Standard two-dimensional images, spectral and color
flow Doppler, and tissue Doppler interrogation were ob-
tained. Measurements were determined from the mean
of 3 cardiac cycles in accordance with guidelines of the
American Society of Echocardiography [21]. Early myocar-
dial tissue Doppler relaxation velocities (E’) were mea-
sured at the lateral, septal, anterior, and inferior aspects of
the mitral annulus. Global E’ velocity was determined by
averaging these four values. All echocardiographic studies
were analyzed offline by the echocardiographic core
laboratory (The Johns Hopkins Echocardiography
Research Laboratory, Baltimore, Maryland, USA), blinded
to genotype status.
Biomarkers
Blood samples were obtained at the time of cardiac im-
aging, processed within 60 min of phlebotomy, and stored
at −80 degrees Celsius prior to analysis. Assays for NT-
proBNP (Roche, Indianapolis, IN), galectin-3, soluble ST,
and supersensitive cardiac troponin I (Singulex, Atlanta,
Georgia, USA) were performed by the biomarker core la-
boratory blinded to clinical and genetic status.
Statistical analysis
Continuous data are presented as mean ± standard devi-
ation (SD), and categorical variables are summarized
with frequencies and percentages. Generalized linear re-
gression was used to compare baseline characteristics
and LA volume and function across the three groups (G
+/LVH+, G+/LVH-, G−/LVH- controls) adjusting for
age, gender and body surface area (BSA). The clustered
robust standard errors option in STATA was used in the
linear regression model to account for observations
clustering within family. Post-hoc Bonferroni-corrected
P values <0.017 (0.05/3 groups for comparison) were
considered to indicate statistical significance for multiple
comparisons across the three groups. Intra-observer
variability was not performed but inter-observer variabil-
ity was tested by a second analysis. The coefficient of
variation for each of the measures of LAV was calculated
as the SD divided by the mean. Multivariate linear
regression was used to examine the relationship between
LAV and function measures and other echocardio-
graphic, CMR and biomarker parameters by using LAV
and function measures as the outcome (Y) and other
echo, CMR and biomarker parameters as the predictor
(X), adjusting for age, gender, BSA and familial relation-
ships. Linear regression models were also used to assess
the association between measures of LA function and
controls, preclinicals and overt HCM subjects further
stratified by extent of LGE. A cut-off value of 4 % was
used corresponding to the median value of LGE. Stata
14.1 was used for statistical analysis (StataCorp LP,
College Station, Texas, USA).
Results
Basic demographics of the study population are pre-
sented in Table 1. Mean age, gender, blood pressure and
BMI did not differ between the control (N = 15) and
preclinical groups (N = 24) but overt HCM subjects
(N = 34) were 6 to 9 years older (p < 0.001). LV wall
thickness did not differ between the control and the
preclinical groups. LV wall thickness was greater in the
overt HCM group as compared to preclinical and
control cohorts (p < 0.001 for both). LVEF and LV mass
was similar between controls and preclinical subjects
but was higher in subjects with overt HCM (<0.01 for
both). LV end diastolic volume and maximal LV outflow
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tract velocity did not differ between the 3 groups. Serum
NT-proBNP levels were significantly higher in the overt
HCM group compared with controls and preclinical
HCM (p < 0.001 for both). LGE was only observed in the
overt HCM group but not in the control and preclinical
cohorts.
The analysis of LA size was performed by two reviewers.
We found a mean bias of 1.6 ± 8.5 mls for the LAVmin, of
2.9 ± 6.1 mls for the LAVmax and of 1.6 ± 5.8 mls for the
LAVbac between reviewers, with a coefficient of variation
ranging from 0.11 to 0.19. Representative images are
provided in Fig. 1. LAV indexed to BSA were numerically
larger in overt HCM subjects, but did not differ signifi-
cantly between the control, preclinical HCM and overt
HCM subjects after adjustment for age, gender, BSA and
family relationships (Table 2). In contrast, measures of LA
function differed between the 3 groups, as summarized in
Table 2. The most consistent relationship was observed
for LATEmF, which was lower in both the preclinical
HCM group (64 ± 8%) and the overt HCM group (59 ±
Table 1 Baseline characteristics in sarcomere mutation carriers with and without left ventricular hypertrophy compared to healthy
mutation-negative family member controls
G+/LVH+
HCM
(N = 34)
G+/LVH-
Preclinical
(N = 24)
G−/LVH-
Control
(N = 15)
P-value*
overall
P-value*
Preclinical
vs Control
P-value*
HCM
vs Preclinical
P-value*
HCM
vs Control
Age, years 33 ± 12 27 ± 10 24 ± 6 <0.001 0.1 <0.001 <0.001
Male, n (%) 25 (74%) 12 (50%) 7 (47%) 0.003 0.8 0.008 0.007
G+ mutation, n (%)
MYH7 6 (18%) 11 (46%) 0
MYBPC3 21 (62%) 10 (42%) 0
TNNT2 5 (14%) 1 (4%) 0
TNNI3 1 (3%) 1 (4%) 0
MYL2 1 (3%) 0 (0%) 0
MYL3 0 (0%) 0 (0%) 0
ACTC 0 (0%) 1 (4%) 0
BMI,kg/m2 28.0 ± 4.3 24.0 ± 3.8 27.0 ± 4.5 0.4 0.6 0.2 0.4
SBP, mmHg 120 ± 11 115 ± 13 122 ± 14 0.7 0.5 1.0 0.7
DBP, mmHg 70 ± 7 70 ± 8 71 ± 9 0.6 0.8 0.4 0.7
IVS, mm 16.0 ± 5.3 9.0 ± 1.2 8.9 ± 1.2 <0.001 0.5 <0.001 <0.001
PW, mm 10.0 ± 2.2 7.9 ± 1.2 7.8 ± 1.6 <0.001 0.3 <0.001 <0.001
Maximal LVWT, mm 16.0 ± 5.1 10.0 ± 2.1 9.7 ± 1.5 <0.001 0.7 <0.001 <0.001
LVEF, % 66 ± 9.4 63.0 ± 6.3 60.0 ± 4.4 0.003 0.8 0.008 <0.001
Max LVOT, m/s 1.3 ± 0.2 1.3 ± 0.2 1.6 ± 0.5 0.036 0.7 0.052 0.2
LV mass, g 189 ± 53 121 ± 29 136 ± 34 <0.001 0.1 <0.001 <0.001
LV massi, g/m2 93 ± 24 66 ± 15 72 ± 15 <0.001 0.2 <0.001 0.012
LVEDVi, ml/ m2 45 ± 14 47 ± 9.3 51 ± 14 0.4 0.5 0.6 0.4
Septal e’ (cm/s) 9.8 ± 2.9 12 ± 2.0 14 ± 2.0 <0.001 0.003 0.047 <0.001
Septal e’/a’ ratio 1.2 ± 0.4 1.7 ± 0.5 1.9 ± 0.6 0.001 0.026 0.3 <0.001
Lateral e’ (cm/s) 14 ± 4.2 16 ± 2.4 16 ± 3.0 0.4 0.6 0.5 0.6
Lateral e’/a’ ratio 1.7 ± 0.8 2.2 ± 1.0 2.5 ± 1.0 0.15 0.6 0.7 0.2
Global E’, cm/s 12 ± 3.4 15 ± 1.9 16 ± 2.3 <0.001 0.1 <0.001 <0.001
Log-NT-proBNP, pg/mL 286 ± 464 51 ± 43 30 ± 28 <0.001 0.5 <0.001 <0.001
LGE, n, % present 17 (50%) 0 (0%) 0 (0%) – – – –
LVH was based on echocardiographic core laboratory measurements, defined as a maximal LV wall thickness (LVWT) ≥12 mm in adults or a z-score ≥ 3 in participants
<18 years of age. LV left ventricular, SBP systolic blood pressure, DBP diastolic blood pressure, BSA body surface area, IVS interventricular septum thickness measured by
echocardiography, PW posterior wall thickness measured by echocardiography, Max LVWT maximal left ventricular wall thickness, measured by MRI, defined as the
largest measurement in each of four segments (anterior and posterior septal, lateral and inferior), LVEF left ventricular ejection fraction, Max LVOTmaximal left ventricular
outflow tract velocity, LVEDVi Left ventricular End Diastolic Volume indexed to BSA, E’ tissue Doppler early diastolic myocardial relaxation velocity, LGE late gadolinium
enhancement. Values represent mean and SD unless otherwise indicated
*Adjusted for age, gender, BSA and family relationships; P values ≤0.017 were considered to indicate statistical significance, applying Bonferroni correction for
multiple comparisons across the three groups
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10%) as compared to normal controls (70 ± 7%; p = 0.002
and p = 0.005, respectively; Table and Fig. 1a). LATEmF
did not differ significantly comparing overt with preclin-
ical HCM (p = 0.2, Table 2). Additionally, LAPEmF was
lower in the overt HCM group (35 ± 11%) as compared to
controls (47 ± 10%, p = 0.006; Table 2 and Fig. 2b). In ana-
lyses further stratified by the extent of LGE, overall,
LATEmF and LAPEmF showed an incremental decline in
control, preclinical and overt HCM groups; smallest in in-
dividuals with more LGE enhancement (p < 0.001 for
trend for both; Fig. 3a and b). This pattern was not seen
for LAAEmF (p = 0.1, Fig. 3c). Furthermore, while defin-
ing cut-offs to differentiate control from overt HCM, and
control from preclinical patients is beyond the scope of
this study, measurement of the area under the curve
(AUC) for LA function yield the following results: the
overall AUC for LATEmF is 0.28 for preclinical and 0.23
for HCM. Using a cutoff of 58% for LATEmF, the AUC is
0.60 for preclinical and 0.60 for HCM. A LATEmF cutoff
of 28% is 100% sensitive and 0% specific for HCM, cor-
rectly classifying 63% of subjects. A LAREmF cutoff of
47.5% is 100% sensitive and 0% specific for preclinical sta-
tus, correctly classifying 56% of subjects.
Multivariate regression models were constructed to as-
sess the relationship between LA function and measures of
cardiac structure, function and serum biomarkers (Table 3).
All 3 measures of LAV were positively correlated with LV
mass, the extent of LGE, and serum NT-proBNP after
adjustment for age, gender, BSA and family relationship
(p ≤ 0.01 for all, Table 3). In analyzing LA function, both
LATEmF and LAPEmF were inversely correlated with these
metrics (p < 0.05 for all), as well as with interventricular
septal thickness (p ≤ 0.001 for both). LV end-diastolic
volumes and LV end-systolic volumes were correlated with
LAVmax but not any measures of LA function. Tissue
Doppler early diastolic myocardial relaxation velocity (glo-
bal E’) was positively associated with LAPEmF (p = 0.05)
and negatively associated with LAVmin, LAVbac (p < 0.05
for both). No measure of LAV or function correlated with
LVEF or serum levels of high sensitivity troponin I, matrix
metalloproteinase-1 (MMP1), or matrix metalloproteinase
inhibitor-1 (TIMP1).
Discussion
In this study, we leveraged a robustly characterized
study population to investigate whether CMR-derived
measures of LA size and function differed between
healthy controls and sarcomere mutation carriers with
preclinical and overt HCM. We identified the follow-
ing major findings: 1. LAV did not significantly differ
between mutation carriers with preclinical or overt
disease or controls; 2. LA dysfunction, reflected by
Fig. 1 Representative CMR images from a control case (a), pre-clinical case (b) and an overt HCM case (c)
Table 2 CMR Imaging assessment of left atrial volumes and function in sarcomere gene mutation carriers with and without left
ventricular hypertrophy compared to healthy family members
G+/LVH+
Overt HCM
(N = 34)
G+/LVH-
Preclinical
(N = 24)
G−/LVH-
Controls
(N = 15)
P-value
overall*
P-value*
Preclinical
vs Control
P-value*
HCM vs
Preclinical
P-value*
HCM vs
Control
LAV Max/BSA, ml/m2 46 ± 18 32 ± 12 33 ± 9 0.031 0.83 0.050 0.13
LAV BAC/BSA, ml/m2 31 ± 16 20 ± 9 18 ± 6 0.015 0.56 0.050 0.10
LAV Min/BSA, ml/m2 20 ± 12 12 ± 5 10 ± 4 0.019 0.20 0.047 0.12
LAPEmF, % 35 ± 11 41 ± 11 47 ± 9 0.002 0.077 0.23 0.006
LAAEmF, % 38 ± 11 39 ± 5 43 ± 9 0.033 0.060 0.46 0.074
LATEmF, % 59 ± 10 64 ± 8 70 ± 7 <0.001 0.002 0.20 0.005
LVH was based on echocardiographic core laboratory measurements, defined as a maximal LV wall thickness (LVWT) ≥12 mm in adults or a z-score ≥ 3 in participants
<18 years of age. LAV left atrial volume, BAC before atrial contraction, BSA body surface area, LATEmF Total left atrial function, LAPEmF left atrial passive function, LAAEmF
left atrial active function. Values represent mean and SD unless otherwise indicated
*Adjusted for age, gender, BSA and family relationships; P values ≤0.017 were considered to indicate statistical significance, applying Bonferroni correction for
multiple comparisons across the three groups
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reduced LATEmF, is detectable in sarcomere mutation
carriers with both preclinical and overt HCM compared
with healthy controls; 3. Patients with overt HCM, par-
ticularly those with the greatest amount of LGE, demon-
strated the most marked reduction of LA function, with
decreased LATEmF and LAPEmF; 4. Impaired LA func-
tion and increased LV volumes were associated with
higher serum NT-proBNP levels and a greater extent of
LGE.
These data provide additional insights regarding early
phenotypic manifestations in preclinical HCM sarco-
mere mutation carriers. Our work suggests that changes
in LA function precede changes in LA size in the patho-
genesis of HCM sarcomere mutations. In the preclinical
cohort, all 3 measures of LA size were similar to those
of control subjects. Yet when LA function was assessed,
the LATEmF was lower in preclinical HCM, and re-
duced in overt HCM. Given our prior work demonstrat-
ing increased extracellular volume fraction, a
quantitative measure of the extent of extracellular ex-
pansion and a marker of interstitial fibrosis, in preclin-
ical HCM subjects [3], we speculate that the impaired
LA function seen in this cohort reflects altered myocar-
dial tissue properties. The reduction in total LA function
was primarily reflected in the passive emptying compo-
nent, while the active emptying function was less
affected.
Another interesting finding of this study was that the
overt HCM group had significantly lower LATEmF and
LAPEmF compared to preclinical HCM and controls.
Further, when the overt HCM group was stratified by
the presence or absence and extent of LGE, most of this
difference was due to overt HCM subjects with a greater
extent of LGE. We speculate that the development of
fibrotic changes in the ventricular myocardium may
precipitate a decline in LA function, particularly
LAPEmF. Although a primary atrial myopathy may also
be present, these findings suggest that alterations in
myocardial tissue composition may also drive the devel-
opment of LA dysfunction in HCM.
While defining cut-offs to differentiate control from
overt HCM, and control from preclinical patients is
beyond the scope of this study (due to the limitations
of sample size as well as the fact that we do not have
data as to whether any of our preclinical progress to
overt HCM), we provide AUC results. However, this
study focuses instead on metrics of LA size and func-
tion to better characterize the pathophysiologic im-
pact of sarcomere mutations and therefore help
elucidate underlying disease biology.
Fully understanding the clinical implications of impaired
LA function in either overt or preclinical HCM will re-
quire further longitudinal investigation. However, a reduc-
tion in LA function has been shown to have prognostic
implications in broad populations [9, 10]. For example,
among patients referred for a stress CMR, a reduction in
LAPEmF was shown to be a significant predictor of ad-
verse cardiac events [10]. Similarly, among patients with
atrial fibrillation, a reduction in LAPEmF was shown to be
a robust predictor for recurrence after pulmonary vein
isolation [10]. In this study, LA total function was abnor-
mal and passive function trended lower in the preclinical
group. It remains to be studied whether reduced LA func-
tion will be associated with earlier progression to overt
(See figure on previous page.)
Fig. 2 Scatterplots depicting the measured (a) Total Left Atrial Function (LATEmF) (b) Left Atrial Passive Function (LAPEmF) and (c) Active
(LAAEmF) Emptying Function in Normal Controls (G-LVH-), subjects with sarcomere mutations without Left Ventricular Hypertrophy (preclinical, G
+ LVH-), and sarcomere mutation HCM subjects with overt LV hypertrophy (G + LVH+). Mean values are depicted by horizontal lines. *P values
≤0.017 versus control after adjusting for age, gender, BSA and family relationships
a
b
c
Fig. 3 Bar graphs depicting the measured (a) Total (LATEmF) and
(b) Passive (LAPEmF) and (c) Active (LAAEmF) Emptying Function in
Normal Controls (G-LVH-), subjects with sarcomere mutations
without LVH (preclinical, G + LVH-), and sarcomere mutation HCM
subjects with overt LVH (G + LVH+) further stratified by having no
LGE, ≤4% LGE and >4% LGE by CMR assessment. Adjusted for age,
sex and BSA
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HCM, a greater susceptibility to atrial fibrillation, more
prominent symptoms of heart failure, and/or poorer prog-
nosis in these subjects. However, some prior data have
shown the association between measures of LA size and
function and adverse outcomes in HCM [7, 8]. For ex-
ample, in a study of 242 HCM patients Debonnaire and
colleagues showed than LAV and LA strain were predict-
ive of new onset AF in patients with HCM [8].
The penetrance or clinical expression of a HCM gene
mutation is age dependent and commonly occurs dur-
ing young adulthood. When phenotypic conversion
does occur, LV wall thickness can increase rapidly and
the pathological manifestations of HCM may arise sud-
denly. In line with its natural history, subjects with
overt HCM in this study were slightly older than pre-
clinical and control groups. Much has yet to be under-
stood of the preclinical stages of HCM. In subjects who
are at risk, based on their family history and genetic
makeup, it is currently unpredictable when and if the
overt HCM will manifest. Developing non-invasive
tools to potentially identify those subjects at greater
risk for disease onset would be important for clinical
management. These subjects could potentially be
followed more closely with physician visits and echo-
cardiographic assessment.
Our study has several limitations. We describe a
small study group without follow up to evaluate clin-
ical outcomes or longitudinal disease evolution. As an
observational study, inferences about causality cannot
be determined. Furthermore, we did not measure
atrial LGE or measure the ECV to correlate with our
finding of LA dysfunction in sarcomere mutation car-
riers. Lastly, 20% of the cohort did not have both 2
and 4-chamber views needed to quantify LA function.
However, when we compared baseline characteristics
between those subjects that underwent CMR and had
quantifiable LA function versus those that were un-
able to be quantified, we found no significant differ-
ences between groups.
Conclusion
In conclusion, in a well-characterized and genotyped
cohort of subjects with preclinical HCM, overt HCM
and familial controls, we found that LA dysfunction is
detectable in preclinical HCM subjects before the pres-
ence of LA enlargement or LVH. Furthermore, LA dys-
function is more pronounced as LVH and ventricular
fibrosis are manifest. Impaired LA function appears to
have physiologic relevance, being associated with a
greater extent of LGE and higher NT-proBNP levels.
These data support the hypothesis that HCM is a pro-
gressive disorder in which at-risk sarcomere mutation
carriers begin to have physiological manifestations be-
fore clinical criteria for overt disease are met.
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